Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, presents the rationale and design for the PREVAIL trial (NCT05556096), a Phase III study of ALXN1720 in adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). ALXN1720 is a novel bispecific antibody that binds to complement component 5 (C5) and albumin, which increases its half-life, facilitating weekly dosing. Around 200 patients will be randomized to receive ALXN1720 or placebo. PREVAIL consists of a 4-week screening period, a 26-week randomized controlled treatment phase, and a 96-week open-label extension period. The trial is currently active and recruiting patients in multiple countries. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research support paid to institution: Alexion Pharmaceuticals, Argenx, Cartesian Therapeutics, The Centers for Disease Control and Prevention, Millennium/Takeda Pharmaceuticals, National Institutes of Health, PCORI, Ra Pharmaceuticals (now UCB)
Honoraria: Alexion Pharmaceuticals, Argenx, Biologix Pharma, Ra Pharmaceuticals (now UCB), F. Hoffmann-LaRoche Ltd, Immunovant, Merck EMB Serono, NMD Pharma, Novartis Pharma, Regeneron Pharmaceuticals, Sanofi US, Toleranzia AB, Horizon Therapeutics, Zai Labs
Stock dividends: Johnson & Johnson, Pfizer, General Electric, GlaxoSmithKline, GE Healthcare, Viatris